

Please type a plus sign (+) inside the box → ☐

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	08/728,463
Filing Date	October 10, 1996
First Named Inventor	Lonberg, Nils, et. al.
Group Art Unit	1644
Examiner Name	DeCloux, Amy
Attorney Docket Number	14643009020

RECEIVED

MAR 20 2001

TECH CENTER 1600/2900

Total Number of Pages in This Submission

7

## ENCLOSURES (check all that apply)

☒ Fee Transmittal Form

☐ Fee Attached

☒ Amendment / Response

☐ After Final

☐ Affidavits/declaration(s)

☐ Extension of Time Request

☐ Express Abandonment Request

☐ Information Disclosure Statement

☐ Certified Copy of Priority Document(s)

☐ Response to Missing Parts/ Incomplete Application

☐ Response to Missing Parts under 37 CFR 1.52 or 1.53

☐ Assignment Papers (for an Application)

☐ Drawing(s)

☐ Licensing-related Papers

☐ Petition Routing Slip (PTO/SB/69) and Accompanying Petition

☐ Petition to Convert to a Provisional Application

☐ Power of Attorney, Revocation Change of Correspondence Address

☐ Terminal Disclaimer

☐ Request for Refund

☐ CD, Number of CD(s)

☐ After Allowance Communication to Group

☐ Appeal Communication to Board of Appeals and Interferences

☐ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)

☐ Proprietary Information

☐ Status Letter

☒ Other Enclosure(s) (please identify below):

Return receipt postcard

Remarks

The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm and Individual name

Townsend and Townsend and Crew LLP

Andrew T. Serafini, Ph.D.

Reg No. 41,303

Signature

*Andrew T. Serafini*

Date

March 12, 2001

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date:

March 12, 2001

Typed or printed name

Andrew T. Serafini, Ph.D.

Signature

*Andrew T. Serafini*

Date

March 12, 2001

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3132465 v1

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Attorney Docket No.: 14643-009020US

Assistant Commissioner for Patents  
Washington, D.C. 20231

On MARCH 12, 2001

TOWNSEND and TOWNSEND and CREW LLP

By: *Andrew T. [Signature]*



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

LONBERG *et al.*

Application No.: 08/728,463

Filed: October 10, 1996

For: TRANSGENIC NON-HUMAN  
ANIMALS FOR PRODUCING  
HETEROLOGOUS ANTIBODIES

Examiner: Amy DeCloux, Ph.D.

Art Unit: 1644

RESPONSE/AMENDMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Office Action mailed September 12, 2000, please amend the above-identified application as follows:

**IN THE CLAIMS**

Please cancel claims 13, 14, 22-29, 37, 40, 50, 51, and 53 without prejudice to future prosecution.

Please add the following new claims:

--54. A heavy chain variable region of an immunoglobulin that specifically binds to human CD4, wherein the immunoglobulin is 10C5.

*Sub G.7* 55. An immunoglobulin having heavy and light chain variable regions encoded by SEQ ID NO:205 and SEQ ID NO:206. *hybridoma*  
*wherein produced by the hybridoma*

56. A heavy chain variable region of an immunoglobulin that specifically binds to human CD4, wherein the immunoglobulin is 4D1. *hybridoma*